Sat, Aug 30, 2014, 2:54 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Opexa Therapeutics, Inc. (OPXA) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dont_be_a_poser_dude dont_be_a_poser_dude Sep 8, 2009 3:53 PM Flag

    Tovaxin has nothing to do with Novartis

    Read 'em and weep.....

    More recently, Novartis and Opexa Therapeutics (OPXA) inked a deal giving Novartis control of Opexa’s stem cell program, including its Tovaxin MS therapy. Tovaxin is a personalized T-cell vaccine for relapsing remitting MS prepared by expanding specific subsets of myelin-reactive T-cells. Attenuated cells are reintroduced with a goal of setting up an anti-idiotype network to shift a TH1 mediated response to a Th2 response.

    In 2008, the TERMS phase II study suggested the strong possibility of a therapeutic response similar to that seen with current platform therapies and with no significant side effects. Initiation of a phase III study in relapsing remitting MS is likely by early next year and will serve as a much bigger catalyst for Opexa than for Novartis.

 
OPXA
1.450.00(0.00%)Aug 29 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Splunk, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
GoPro, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT